GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Cyclically Adjusted Book per Share: ₹153.60 (As of Mar. 2026)


NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
73 GF Score
Price ₹2,415.80
GF Value ₹2,619.28
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Book per Share?

GlaxoSmithKline Pharmaceuticals NSE:GLAXO -1.98% 73 Cyclically Adjusted Book per Share is ₹153.60 as of Mar. 2026. GuruFocus rates NSE:GLAXO with a GF Score™ of 73/100 and a GF Value™ of ₹2,619.28 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

GlaxoSmithKline Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was ₹133.845. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹153.60 for the trailing ten years ended in Mar. 2026.

During the past 12 months, GlaxoSmithKline Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-03), GlaxoSmithKline Pharmaceuticals's current stock price is ₹2415.80. GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ₹153.60. GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 15.73.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of GlaxoSmithKline Pharmaceuticals was 20.54. The lowest was 12.93. And the median was 15.78.


GlaxoSmithKline Pharmaceuticals  (NSE:GLAXO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2415.80/153.60
=15.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of GlaxoSmithKline Pharmaceuticals was 20.54. The lowest was 12.93. And the median was 15.78.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Book per Share Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 168.51 153.60

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.51 0.00 162.61 0.00 153.60

NSE:GLAXO vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


NSE:GLAXO
73GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlaxoSmithKline Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=133.845/164.2724*164.2724
=133.845

Current CPI (Mar. 2026) = 164.2724.

GlaxoSmithKline Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201112 114.264 75.359 249.081
201212 118.463 83.774 232.293
201312 117.454 91.425 211.042
201503 144.273 97.163 243.921
201603 128.877 102.518 206.509
201703 118.464 105.196 184.991
201706 0.000 107.109 0.000
201803 121.444 109.786 181.716
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 126.314 118.202 175.546
201906 0.000 120.880 0.000
201909 138.463 123.175 184.661
201912 0.000 126.235 0.000
202003 107.470 124.705 141.569
202006 0.000 127.000 0.000
202009 78.348 130.118 98.913
202012 0.000 130.889 0.000
202103 87.261 131.771 108.784
202106 0.000 134.084 0.000
202109 76.467 135.847 92.467
202112 0.000 138.161 0.000
202203 157.194 138.822 186.013
202206 0.000 142.347 0.000
202209 85.882 144.661 97.525
202212 0.000 145.763 0.000
202303 102.787 146.865 114.970
202306 0.000 150.280 0.000
202309 90.879 151.492 98.546
202312 0.000 152.924 0.000
202403 104.934 153.035 112.640
202406 0.000 155.789 0.000
202409 98.739 157.882 102.735
202412 0.000 158.323 0.000
202503 115.185 157.552 120.098
202506 0.000 159.755 0.000
202509 100.805 162.289 102.037
202512 0.000 163.281 0.000
202603 133.845 164.272 133.845

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ₹153.60 mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Cyclically Adjusted Book per Share of ₹153.60 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' Cyclically Adjusted Book per Share too high?
GlaxoSmithKline Pharmaceuticals' current Cyclically Adjusted Book per Share is ₹153.60. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Cyclically Adjusted Book per Share compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' Cyclically Adjusted Book per Share of ₹153.60 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current Cyclically Adjusted Book per Share is ₹153.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,619.28, compared to a current price of ₹2,415.80 — trading 7.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is ₹153.60. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Cyclically Adjusted Book per Share is ₹153.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,415.80 is trading 7.8% below its estimated GF Value™ of ₹2,619.28. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLAXO:

  • Cyclically Adjusted Book per Share: ₹153.60
  • GF Value™: ₹2,619.28 vs. price of ₹2,415.80 (7.8% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score

Get the complete analysis for NSE:GLAXO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,415.80
Price
₹2,619.28
GF Value